Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-819 in unresectable pancreatic cancer
NCT00711997Phase 2Completed
- Sponsor
- Anchiano Therapeutics Ltd.
- Start
- Aug 2009
- Primary completion
- Oct 2010
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of inodiftagene vixteplasmid in pancreatic adenocarcinoma (PDAC), sponsored by Anchiano Therapeutics Ltd.. Started Aug 2009; status: completed.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00711997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711997.